NCT00291902View on ClinicalTrials.gov

A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention

PHASE2CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

March 31, 2006

Conditions

Coronary Heart Disease

Interventions

DRUG

SB-681323

Trial Locations (7)

2900

GSK Investigational Site, Hellerup

6100

GSK Investigational Site, Haderslev

6700

GSK Investigational Site, Esbjerg

7400

GSK Investigational Site, Herning

8800

GSK Investigational Site, Viborg

15-276

GSK Investigational Site, Bialystok

60-355

GSK Investigational Site, Poznan

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY